drugset / Trial / NCT03502694

Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus

NCT03502694

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine in hospitalized adult participants infected with human metapneumovirus (hMPV - a virus closely related to respiratory syncytial virus (RSV) and has been identified as an important cause of acute respiratory infections, affecting all age groups) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity based on nasal hMPV shedding using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) assay.

Timeline

Start
2018-11-05
Primary completion
2019-04-30
Completion
2020-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumicitabine Small molecule 250 mg Oral
Subject Lumicitabine Small molecule 500 mg Oral